Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Karuna Therapeutics, Inc. - Common Stock (NQ:KRTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Karuna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Travelzoo, Semler Scientific, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly higher, with the Dow Jones gaining around 20 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. 
Via Benzinga
Analyst Expectations for Karuna Therapeutics's Future
 
Via Benzinga
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
ENPH Stock Price Prediction: Can Enphase Energy Really Hit $225?
Enphase Energy (ENPH) stock is continuing to rise higher on Monday after an upgrade on Friday gave the company's shares a boost. 
Via InvestorPlace
UBS Stock Price Prediction: Why This Analyst Says UBS Is a ‘Buy’
UBS (UBS) stock is a hot topic among traders on Monday with one analyst offering a new rating for the financial company's shares. 
Via InvestorPlace
Karuna Therapeutics Says It One Step Closer To Potential Treatment Option After Encouraging Schizophrenia Data
 
Via Benzinga
Why Is Karuna Therapeutics (KRTX) Stock Moving Today?
Karuna Therapeutics (KRTX) stock is on the move Monday after releasing positive results from a Phase 3 clinical trial for KarXT. 
Via InvestorPlace
Karuna Surges To Three-Month High On Another Win In Schizophrenia
The company is soon planning to ask for FDA approval of KarXT. 
Via Investor's Business Daily
The Latest Analyst Ratings for Karuna Therapeutics
 
Via Benzinga
Looking Into Karuna Therapeutics's Return On Capital Employed
 
Via Benzinga
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Zai Lab Limited
Via GlobeNewswire
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023
 
Via Benzinga
Analyst Expectations for Karuna Therapeutics's Future
 
Via Benzinga
5 Analysts Have This to Say About Karuna Therapeutics
 
Via Benzinga
What 5 Analyst Ratings Have To Say About Karuna Therapeutics
 
Via Benzinga
Ciena, Apple And 3 Stocks To Watch Heading Into Monday
With US futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Target To Rally 20%? Here Are 10 Other Analyst Forecasts For Thursday
Bernstein raised the price target for Okta, Inc. (NASDAQ: OKTA) from $80 to $92. Bernstein analyst Peter Weed maintained a Market Perform rating. Okta shares jumped 16.2% to $83.00 in pre-market... 
Via Benzinga
Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Karuna
Via Business Wire
Where Karuna Therapeutics Stands With Analysts
 
Via Benzinga
Expert Ratings for Karuna Therapeutics
 
Via Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
 
Via Benzinga
Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer
From Karuna Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.